GlassScriptPhysician profile
Kyle J Ward
NPI 1124548995
$1,717.73
in general payments reported to CMS, 2019-2025
12 companies · $695 in 2025
The $695 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.45 · 2023: $378 · 2024: $578 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.01 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $417.49 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $256.85 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $221.93 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $195.95 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $150.83 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $146.39 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $122.98 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $59.86 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $42.56 | 2023-2024 | Vraylar |
| Axsome Therapeutics, INC. | $36.81 | 2023-2025 | Auvelity |
| Tris Pharma INC | $34.35 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $31.73 | 2023 | Azstarys, Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.